Yahoo · Nov 6, 2026
All You Need to Know About Revvity (RVTY) Rating Upgrade to Buy
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NYSE · RVTY
Revvity, Inc.
Healthcare · Medical - Diagnostics & Research
$157.02
Down-$3.54 (-2.25%)
Updated Nov 13, 2026, 6:03 PM
SID Score
6.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 12.32B
- P/E ratio
- 51.31
- Dividend yield
- 0.22%
- 52-week range
- $81.22 – $171.74
- Volume
- 1.47M
- Avg. volume
- 1.43M
Price performance · RVTY
RVTY price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
RVTY closed at $157.02 after 21 trading sessions, up 1.49% for the selected period.
- Last close
- $157.02
- Period change
- +1.49%
- Period low
- $150.83
- Period high
- $165.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $156.51 | $159.36 | $153.04 | $157.02 | 1.47M |
| Nov 11, 2026 | $161.07 | $163.29 | $158.21 | $158.25 | 1.17M |
| Nov 10, 2026 | $161.50 | $161.98 | $156.84 | $159.10 | 1.15M |
| Nov 9, 2026 | $157.44 | $161.93 | $154.15 | $160.72 | 1.72M |
| Nov 6, 2026 | $150.83 | $158.96 | $149.38 | $155.11 | 1.68M |
| Nov 5, 2026 | $157.67 | $158.78 | $150.37 | $150.83 | 2.3M |
| Nov 4, 2026 | $167.69 | $167.69 | $155.96 | $159.43 | 2.86M |
| Nov 3, 2026 | $163.01 | $171.74 | $162.21 | $163.48 | 3.37M |
| Nov 2, 2026 | $160.07 | $160.07 | $150.625 | $151.60 | 2.8M |
| Oct 30, 2026 | $164.21 | $164.21 | $155.81 | $157.00 | 3.18M |
| Oct 29, 2026 | $165.32 | $167.30 | $163.05 | $165.78 | 1.53M |
| Oct 28, 2026 | $163.00 | $169.06 | $162.85 | $165.33 | 2.18M |
| Oct 27, 2026 | $158.82 | $162.76 | $156.28 | $161.86 | 1.55M |
| Oct 26, 2026 | $159.37 | $161.67 | $159.10 | $160.39 | 1.09M |
| Oct 23, 2026 | $156.35 | $159.05 | $152.73 | $158.77 | 1.11M |
| Oct 22, 2026 | $156.18 | $161.64 | $154.87 | $157.36 | 1.78M |
| Oct 21, 2026 | $154.44 | $159.48 | $152.71 | $156.61 | 2M |
| Oct 20, 2026 | $152.64 | $157.575 | $152.19 | $156.01 | 1.4M |
| Oct 19, 2026 | $153.89 | $156.8673 | $150.71 | $150.94 | 1.26M |
| Oct 16, 2026 | $154.44 | $155.50 | $151.61 | $152.64 | 1.34M |
| Oct 15, 2026 | $151.91 | $156.86 | $148.83 | $154.71 | 2.37M |
Latest RVTY news
The latest Smart Investors Daily articles mentioning RVTY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RVTY research
Overview
Company profile and research snapshot.
Company profile
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $110.25
- Implied upside
- —
- Analysts
- 25
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 4, 2026 | JP Morgan | Neutral | — |
| Nov 4, 2026 | Barclays | Equal-Weight | — |
| Nov 4, 2026 | RBC Capital | Sector Perform | — |
| Nov 4, 2026 | TD Cowen | Buy | — |
| Nov 4, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 6, 2026
ETFs Are Net Sellers of Revvity (RVTY) on Nov. 4
ETFs sold a net $25.3 million of Revvity (RVTY) on Wednesday, Nov. 4.
Benzinga · Nov 4, 2026
JP Morgan Maintains Neutral on Revvity, Raises Price Target to $160
JP Morgan analyst Casey Woodring maintains Revvity (NYSE:RVTY) with a Neutral and raises the price target from $155 to $160.
Benzinga · Nov 4, 2026
TD Cowen Maintains Buy on Revvity, Raises Price Target to $185
TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $175 to $185.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
